Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource-Constrained Settings–Implementation Science Network (PATC3H-IN)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Oct 20, 2026
Can you apply?
This grant is for researchers and institutions conducting implementation science research on adolescent HIV prevention and treatment. Eligible applicants include academic medical centers, research institutions, and organizations with capacity to conduct rigorous implementation science studies in low- and middle-income countries. Projects must focus on developing scalable, low-resource care delivery models for adolescents affected by HIV, with findings applicable to marginalized and high-burden U.S. populations.
The grant supports comparative effectiveness research, implementation strategy testing, and program evaluation across international health systems. Priority is given to studies that generate evidence on intervention uptake, viral suppression outcomes, and care model sustainability. Applicants must demonstrate experience with adolescent HIV populations and implementation science methodology.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Oct 20, 2026 Applications open
- Oct 28, 2027 Application deadline in 372 days
- Jul 1, 2028 Award announced
- Jul 1, 2028 Project start
Program description
The Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings–Implementation Science Network (PATC3H-IN) conducts implementation science (IS) research on adolescent HIV. PATC3H-IN develops scalable, low-resource care delivery models in low- and middle-income countries that can be adapted for marginalized and high-burden US populations. It aligns with NIH’s Unified Strategy prioritizing IS to expand uptake of and access to HIV interventions. PATC3H-IN will study and test the impact of implementation strategies on adolescent HIV incidence, prevention uptake, and viral suppression, providing a strong evidence base for interventions that can be used in US-based programs.
Resource-constrained, high-burden settings outside the US provide an unparalleled environment for adolescent HIV implementation science that aims to strengthen HIV care in the US. Higher HIV incidence and prevalence allow researchers to rigorously evaluate implementation strategies in large adolescent populations. The studies produce robust evidence on effectiveness, scalability, adaptation, and sustainability. These studies complement U.S.-based research by generating evidence that is difficult to obtain within the smaller, geographically dispersed population of adolescents living with HIV in the US. In addition, they test implementation strategies across a wide range of health systems and community settings.
Limited local resources outside the US also drive innovation through necessity. Health systems develop efficient, scalable models of care–including differentiated service delivery, task sharing, peer support, digital adherence interventions, and community-based care–to maximize impact with available resources. Many international HIV programs also operate within coordinated care systems that can rapidly test, adapt, and refine service delivery strategies through continuous, data-driven evaluation. This operational flexibility supports rapid-cycle learning and implementation at a pace that is often difficult to achieve in the more complex and decentralized U.S. healthcare system. Combined with access to large adolescent cohorts, these settings provide an exceptional platform for generating rigorous, practice-ready implementation evidence.
The innovations are directly relevant to the United States, where adolescents and young adults living with HIV are projected to incur nearly $17 billion in lifetime healthcare costs, averaging approximately $685,000 per person. Despite advances in HIV prevention and treatment, nearly 39,000 people receive new HIV diagnoses each year in the United States. About one in five of these new cases occur among adolescents and young adults, and many individuals still receive their diagnosis at later stages of infection. Many U.S. adolescents affected by HIV face the same barriers as youth in resource-constrained settings, including poverty, housing instability, stigma, transportation challenges, workforce shortages, and fragmented care. As a result, implementation strategies that succeed in resource-constrained settings can help build more resilient and scalable models of care in the US. Global adolescent HIV implementation research provides critical evidence needed to achieve the goals of the Ending the HIV Epidemic in the U.S. initiative by accelerating the translation of effective, resilient, and cost-conscious models of care into domestic practice.
Adolescents and young people represent a growing share of people living with HIV in the US and worldwide. Comprising Clinical Research Centers and a Data and Coordinating Center, PATC3H-IN addresses this gap by supporting IS research to prevent HIV acquisition among at-risk adolescents and improve care outcomes for youth living with HIV. Grant authorities allowing the Eunice Kennedy Shriver National Institute of Child Health and Human Development to forecast this opportunity include: 42 U.S.C. 281 (Sec. 401); 42 U.S.C. 285g (Sec. 448); 42 USC 284h (Sec. 409D).
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
How to apply
Application links
Key dates & requirements
Required documents
- R01 application forms (SF-424, PHS 398, or equivalent)
- Project narrative with implementation science framework
- Preliminary data from proposed setting
- International partnership letters and MOUs
- Budget and budget narrative
- Biographical sketches of key personnel
- Institutional Review Board or ethics approval documentation
Program contact
- 👤 Maternal and Pediatric Infectious Diseases Branch (MPIDB) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- 📧 nichd_mpidb_nofos@mail.nih.gov
- 📞 Please contact via e-mail
Funding track record
Recent awards under CFDA 93.865 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$1,073,967,938
-
$719,372,575
-
$282,005,487
-
$155,556,396
-
$155,482,198
-
$103,665,364
-
$74,151,078
-
$72,701,366
-
$56,043,433
-
$49,667,365
Top States by Funding
- WA 1 awards $1,074.0M
- NC 7 awards $928.6M
- MD 4 awards $513.0M
- MA 3 awards $190.0M
- PA 3 awards $151.4M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.865). How funding has trended year over year.
| 2024 | $1,282,226,682 | |
| 2025 | $1,333,391,690 | |
| 2026 est. | $184,920,723 |
FAQ
Who is eligible to apply for PATC3H-IN funding?
Academic institutions, research centers, and organizations with implementation science expertise and experience with adolescent HIV populations. International collaborations are required; studies must be conducted in low- and middle-income countries.
What geographic locations are supported?
Research must be conducted in resource-constrained, low- and middle-income country settings outside the U.S., with findings applicable to U.S.-based adolescent populations.
What types of activities does this grant support?
Implementation science research on HIV prevention and treatment models, intervention effectiveness studies, care delivery innovation testing, and program evaluation using continuous, data-driven approaches.
How competitive is this funding?
This is highly competitive NIH funding requiring rigorous implementation science design, strong preliminary data, and demonstrated capacity to conduct international research with large adolescent cohorts.
What is the typical funding timeline?
The fixed deadline is October 28, 2027. Award amount and project duration are determined based on application scope and reviewer recommendations.
💡 Tips for applicants
- Ground your application in NIH's Unified Strategy on implementation science and the Ending the HIV Epidemic initiative goals.
- Emphasize how your international research setting enables rigorous testing impossible in fragmented U.S. healthcare systems.
- Include strong preliminary data from your proposed setting showing feasibility and adolescent population size.
- Detail how findings will translate to U.S. marginalized and high-burden populations facing similar barriers.
- Build partnerships with international health systems capable of rapid-cycle learning and data-driven adaptation.
⚠️ Common mistakes
Proposing research that lacks clear relevance to U.S. HIV priorities or adolescent populations. Underestimating complexity of international research logistics, regulatory requirements, and community engagement. Failing to demonstrate how specific implementation strategies will scale or adapt across different health system contexts.
Similar grants
- OPEN Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional) — National Institutes of Health
- OPEN LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE) — National Institutes of Health
- OPEN Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required) — National Institutes of Health
- OPEN HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional) — National Institutes of Health
- OPEN AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional) — National Institutes of Health